絞り込み

16644

広告

がん種類別・ステージ別 5年生存率の詳細データ (NHK)

国立がん研究センターが発表した、5年生存率のがんの種類・ステージ別のデータは以下のとおりです。全体の生存率が高い順に示します。 前立腺がん ▽ステージ1=100...

  1. がん 5年生存率 全体で66.4% 最高...
  2. 首位アジルバがオルメテックを大きく突き放...
  3. 【動画】この薬を食前に飲んで下さい。 (...
  4. 遺伝性乳がん 予防切除、保険適用 中医協...

ニュース一覧

Therapeutic Management of the Overlapping Syndromes of Atypical Parkinsonism.

著者 Giagkou N , Stamelou M
CNS Drugs.2018 Jul 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)
Progressive supranuclear palsy, corticobasal degeneration and multiple system atrophy account for approximately 10% of neurodegenerative parkinsonism. Considerable clinical overlap exists between these disorders that extends to features considered characteristic of each disease. Clinical diagnostic criteria have attempted to increase the accuracy of clinical diagnosis as accurate diagnosis is necessary to inform prognosis and to facilitate the recognition of disease-modifying treatments. Currently no such treatment exists. Nevertheless, many clinical trials aiming to change the natural history of these diseases are ongoing. The spread and accumulation of abnormal proteins are among the pathophysiological mechanisms targeted. For the time being, however, only symptomatic treatment is available. Levodopa is used to treat parkinsonism, but patients usually show a poor or transient response. Amantadine is also used in practice for the same indication. Botulinum toxin can alleviate focal dystonic manifestations. Addressing non-motor manifestations is limited by the potential of available drugs to impact on other aspects of the disease. Most of the new symptomatic formulations under study are focused on orthostatic hypotension in multiple system atrophy. Exercise, occupational, physical, and speech therapy and psychotherapy should always accompany pharmacological approaches.
PMID: 30051337 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード